藥明康德榮膺CDP氣候變化和水安全“雙A”評(píng)級(jí) | Bilingual News

上海，2026年1月19日 – 藥明康德今日宣布，公司在2025年全球環(huán)境信息研究中心（CDP）評(píng)估中，在氣候變化和水安全兩個(gè)議題上均入選“A級(jí)”榜單。“A級(jí)”是CDP在相關(guān)領(lǐng)域授予的最高等級(jí)，這一認(rèn)可充分體現(xiàn)了藥明康德在氣候變化和水資源管理方面的突出表現(xiàn)和對(duì)可持續(xù)發(fā)展的堅(jiān)定承諾。

CDP作為一家全球性非營(yíng)利組織，運(yùn)營(yíng)著全球唯一的獨(dú)立環(huán)境信息披露系統(tǒng)，協(xié)助企業(yè)、資本市場(chǎng)、城市等管理其環(huán)境影響。CDP的年度評(píng)估流程與國(guó)際主流環(huán)境框架和信息披露標(biāo)準(zhǔn)保持一致，被廣泛視為評(píng)估企業(yè)環(huán)境管理水平的權(quán)威標(biāo)準(zhǔn)。在本次評(píng)估中，藥明康德首次入選氣候變化“A級(jí)”榜單，并連續(xù)第二年榮登水安全“A級(jí)”榜單。

“同時(shí)入選CDP氣候變化和水安全‘A級(jí)’榜單，體現(xiàn)了藥明康德始終致力于推動(dòng)醫(yī)藥領(lǐng)域的可持續(xù)創(chuàng)新。”藥明康德聯(lián)席首席執(zhí)行官兼可持續(xù)發(fā)展委員會(huì)主席楊青博士表示：“作為全球醫(yī)藥和生命科學(xué)領(lǐng)域值得信賴的合作伙伴，藥明康德在助力客戶加速新藥和突破性療法問(wèn)世的同時(shí)，持續(xù)將環(huán)境責(zé)任融入公司運(yùn)營(yíng)，致力于構(gòu)建更健康、更可持續(xù)的未來(lái)。”

氣候變化和水資源管理策略是藥明康德踐行環(huán)境保護(hù)承諾的重要組成部分。公司積極識(shí)別和應(yīng)對(duì)環(huán)境相關(guān)的風(fēng)險(xiǎn)與機(jī)遇，不斷強(qiáng)化環(huán)境管理體系，并切實(shí)保護(hù)運(yùn)營(yíng)基地及其周邊自然環(huán)境。同時(shí)，藥明康德圍繞多個(gè)關(guān)鍵環(huán)境管理事項(xiàng)設(shè)立了目標(biāo)，并通過(guò)監(jiān)測(cè)和評(píng)估，實(shí)現(xiàn)量化分析與定期精準(zhǔn)復(fù)盤(pán)。

作為創(chuàng)新的賦能者、客戶信賴的合作伙伴以及全球健康產(chǎn)業(yè)的貢獻(xiàn)者，藥明康德和大多數(shù)客戶一樣，積極踐行對(duì)可持續(xù)發(fā)展的承諾。截至目前，公司連續(xù)五年獲得MSCI ESG領(lǐng)導(dǎo)力評(píng)級(jí)，并在最新的評(píng)估中首次獲得“AAA”最高評(píng)級(jí)；連續(xù)四年入選道瓊斯可持續(xù)發(fā)展指數(shù)（DJSI）；連續(xù)三年入選富時(shí)羅素社會(huì)責(zé)任指數(shù)系列；連續(xù)兩年獲得EcoVadis企業(yè)社會(huì)責(zé)任評(píng)級(jí)“金牌”認(rèn)證。

此外，為進(jìn)一步深化可持續(xù)發(fā)展承諾，藥明康德持續(xù)拓展全球責(zé)任實(shí)踐。公司溫室氣體減排近期目標(biāo)成功通過(guò)了SBTi審核認(rèn)證。同時(shí)，公司已加入聯(lián)合國(guó)全球契約組織（UNGC），承諾支持全球契約十項(xiàng)原則；并加入制藥供應(yīng)鏈倡議（PSCI），成為PSCI供應(yīng)商合作伙伴。

關(guān)于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）是全球醫(yī)藥及生命科學(xué)行業(yè)值得信賴的合作伙伴和重要貢獻(xiàn)者，致力于通過(guò)提供一體化、端到端的新藥研發(fā)和生產(chǎn)服務(wù)，推動(dòng)全球醫(yī)藥健康創(chuàng)新。公司在亞洲、歐洲、北美等地均設(shè)有運(yùn)營(yíng)基地，依托獨(dú)特的“CRDMO”業(yè)務(wù)模式，不斷降低研發(fā)門(mén)檻，助力客戶提升研發(fā)效率，為患者帶來(lái)突破性的治療方案。目前，公司的賦能平臺(tái)正承載著來(lái)自全球30多個(gè)國(guó)家的約6,000家合作伙伴的研發(fā)創(chuàng)新項(xiàng)目，致力于將更多新藥、好藥帶給全球病患，早日實(shí)現(xiàn)“讓天下沒(méi)有難做的藥，難治的病”的愿景。更多信息，請(qǐng)?jiān)L問(wèn)公司網(wǎng)站：www.wuxiapptec.com

WuXi AppTec Receives Double “A” Rating from CDP for Climate Change and Water Security Leadership

SHANGHAI, January 18, 2026 - WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the “A List” for leadership in corporate transparency and performance across both Climate Change and Water Security by CDP (Carbon Disclosure Project). This recognition, which represents CDP’s highest rating in each category, underscores WuXi AppTec’s achievements in climate change and water resource management and its ongoing commitment to sustainable development.

CDP is a global non-profit that runs the world’s only independent environmental disclosure system for companies, capital markets, cities, states and regions to manage their environmental impacts. Its annual assessment process, aligned with major environmental frameworks and disclosure standards, is renowned as a global benchmark for evaluating companies’ environment-related activities. In the latest assessment, WuXi AppTec was named to CDP’s “A List” for Climate Change for the first time and included on CDP’s “A List” for Water Security for the second consecutive year.

“Earning CDP’s ‘A’ rating for both Climate Change and Water Security reflects WuXi AppTec’s unwavering commitment to sustainable pharmaceutical innovation,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s Sustainability Committee. “As a trusted partner to the global pharmaceutical and life sciences industry, we are dedicated to advancing life-saving therapies while integrating environmental stewardship throughout our operations.”

Climate change and water resource management strategies are core components of WuXi AppTec’s commitment to environmental protection. The Company actively addresses environmental risks and opportunities, continuously strengthens its environmental management systems, and effectively safeguards its operational sites and the surrounding natural environment. WuXi AppTec has set targets across multiple key environmental management areas and monitors progress to enable quantitative analysis and regular, precise reviews.

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates sustainability throughout its operations in alignment with the values of its customers and partners. The Company’s leadership in sustainability has been recognized by several prestigious organizations, notably receiving the MSCI ESG Leadership Rating for five consecutive years and achieving its first AAA rating in the most recent assessment. It has also been included in the Dow Jones Sustainability Index (DJSI) for four consecutive years and the FTSE4Good Index Series for three consecutive years. Additionally, the Company has received a Gold Medal in sustainability from EcoVadis for the second consecutive year.

Furthering its sustainability commitments, WuXi AppTec has received validation from the Science Based Targets initiative (SBTi) for its near-term emissions reduction targets. The Company is also a participant in the United Nations Global Compact (UNGC), supporting its ten principles, and serves as a supplier partner to the Pharmaceutical Supply Chain Initiative (PSCI).

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

免責(zé)聲明：本文僅作信息交流之目的，文中觀點(diǎn)不代表藥明康德立場(chǎng)，亦不代表藥明康德支持或反對(duì)文中觀點(diǎn)。本文也不是治療方案推薦。如需獲得治療方案指導(dǎo)，請(qǐng)前往正規(guī)醫(yī)院就診。

版權(quán)說(shuō)明：歡迎個(gè)人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機(jī)構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺(tái)。轉(zhuǎn)載授權(quán)請(qǐng)?jiān)凇杆幟骺档隆刮⑿殴娞?hào)回復(fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。